Roche’s phase III IMvigor211 study of Tecentriq (atezolizumab) in people with locally advanced or metastatic urothelial cancer (mUC) whose disease progressed during or after treatment with a platinum-based chemotherapy (previously treated) has failed to meet its primary endpoint of overall survival (OS) compared to chemotherapy.
Daiichi Sankyo announced the initiation of the ENVISAGE-TAVI AF study of Lixiana by enrolling the first patient in the trial.
Myovant Sciences has reported positive results from a placebo-controlled Phase 2 dose-finding trial evaluating the ability of relugolix to decrease heavy menstrual bleeding in women with uterine fibroids which was conducted by Takeda Pharmaceutical in Japan.
GlaxoSmithKline and Innoviva said that their asthma drug Relvar Ellipta yielded positive results from the Salford Lung Study (SLS) in 4,233 asthma patients treated by their own general practitioner in everyday clinical practice.
Teva Pharmaceutical Industries and Active Biotech announced that CONCERTO trial for laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS) failed to meet its primary endpoint.
Science 37 has raised $29m in Series C funding, led by Glynn Capital Management with participation from GV, to bring clinical trials directly into patients’ homes.
Results from the phase 3 REPROVE study assessing Pfizer's fixed-dose antibacterial combo Zavicefta (ceftazidime-avibactam) in patients with hospital-acquired pneumonia (HAP) demonstrated a comparable cure rate to carbapenem antibiotic therapy, considered the standard of care.
NGM Bio’s NGM282 has met the primary and key secondary endpoints in a Phase 2 trial in nonalcoholic steatohepatitis (NASH) patients.
Ultragenyx Pharmaceutical, Kyowa Hakko Kirin and Kyowa Kirin International have reported positive 24-week data from the randomized, double-blind, placebo-controlled Phase 3 trial of burosumab (KRN23) in X-linked hypophosphatemia (XLH) adult patients.
Relypsa’s Veltassa (patiromer) has demonstrated consistent effficacy and safety in phase 4 Tourmaline study in patients with hyperkalemia.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.